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Evidence-based diagnosis, decision-making, and therapy appear a must these days. Generating and publishing evidence is a tedious job according
to ever new and tightened research practice regulations. Rules will never prevent the typical human behaviour from showing the new thing to
be shinier and the old thing dustier than they really are. The medical community is solicited to concoct a meal that is gullible for patients, au-
thorities, and third-party payers out of the available evidence (after applying some conversion factors correcting the common bias of the re-
searchers), anticipation of what will be the evidence tomorrow, common sense, and digested experience. Examples of misguidance by poorly
produced or misinterpreted evidence are plentiful in interventional cardiology as they are in other disciplines. Coronary stents, for instance,
were first underestimated due to the fact that they were generally used in bailout situations where the outcome remained rather dismal in spite
of the salvaging potential of stents. Then they were overused quite uncritically rather to the detriment of the patient. Nowwith the high quality
of the modern drug-eluting stents (DESs), the overuse persists but is no longer a concern. However, the enhanced potential of DESs compared
with bare-metal stents was poorly exploited for .10 years because of reports that slipped through the meshes of good review and publication
practice to convey the untenable message that bare-metal stents were preferable in many situations. As other examples, use of the fractional flow
reserve (FFR) for decision-making has to be questioned despite prominently published reports recommending it. Fixing a lesion is today easier and
hardly more complication prone than assessing it with the FFR. Closure of the patent foramen ovale may never be properly applied, because the
collection of the understandably requested evidence takes decades, a follow-up duration that makes research unattractive to physicians and
financiers. Transarterial aortic valve replacement, finally, is certain to eventually supplant surgical aortic valve replacement. However, this should
have already been accomplished as a logical progress. The adoption of this remarkable breakthrough technology is slowed down by the quest for
providing randomized evidence in patients, for whom the evidence should rather be derived from already existing studies, and by the quest to
triage all these patients in a heart team, meaning to also keep the surgeons happy, although these patients do not really need them.
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Introduction
When interpreting scientific data, in particular in medicine, there is a
conversion factor to be imputed. It is normal human behaviour and
ubiquitously accepted to be biased for the new thing or technique
reported in a scientific paper. Hence, a comparative study, rando-
mized or not, will show the old and conventional comparator worse
than it really is and the new thing better. Applying this conversion
factor to a study showing a small albeit significant advantage of
the new thing invalidates the claimed significance and perhaps
even annihilates the numerical advantage. A study showing equi-
poise converts into one with inferiority of the new thing, perhaps
even to a significant degree. Only the presence of an apparently
huge advantage of the new thing guarantees a real progress. Yet,
again the conversion factor needs to be applied and may well unveil
this advantage as a rather modest one.
Carrying that thought through, evidence-based medicine, an un-
contestedly laudable product of the last century, loses a number of
realms that are currently considered to be checked off and carved
into stone. Personal interpretation of data and experience must fill
the gaps that were once thought to be closed but are now reo-
pened. And this is not necessarily a bad thing. Collecting evidence
in a randomized fashion, ideally with double-blind, double-dummy,
and sham-controlled design, could well be overrated. Currently, it
is a declared holy grail but that may take bizarre shapes. The rigour
of the leading scientific journals, in particular in medicine where
nothing less than survival is at stake, is meant to protect against
hype and fraud. On the other hand, it may also produce conclusions
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and recommendations ridiculed by common sense. For instance,
pharmaceutical companies like to include large numbers of partici-
pants in randomized trials. This practice has two main reasons that
justify the costs. First, a large trial is more likely to show a small ad-
vantage of the new drug as a significant one. Second, broad inclusion
criteria yield a large target population once a benefit is shown.
As a fictitious example, reading glass producers would have a
great interest in a trial randomizing the entire world population
into two halves. One half would read the newspaper with reading
glasses and the other half without. Beyond doubt, a significant ad-
vantage of using reading glasses would be proved. The conclusion
in the scientific report would be: according to this positive trial on
all comers, newspapers should only be read with reading glasses.
The market for reading glasses would expand from people .40
years (the segment that the study should have been limited to) to
everybody.
Even more grotesquely misleading conclusions can emanate from
poorly conceived or sloppily conducted randomized trials. Current
publication criteria for randomized trials do not allow one to alter
the endpoint of a study after the study has commenced. Neither do
they allow one to hypothesize in the abstract or the final conclu-
sions of the paper on how the results might have been if the design
or endpoints of the study had been chosen differently.
Again fictitious but nonetheless exemplary, 20 people are put on
a plane to find out if it is advantageous to wear a parachute when
jumping off the plane. The analysis of the state of the jumpers had
been fixed and hence published at 1 min after leaving the plane, ig-
noring the fact that jumping off at 5000 m nobody will have reached
the ground at 1 min. The study will show no benefit of wearing a
parachute. In contrast, there will be a slight disadvantage if, for in-
stance, in the group with parachutes one person suffers a scratch
on the cheek sliding into the shoulder straps of the parachute and
one squeezes a thumb closing a buckle of the parachute. While
this would not suffice to recommend against the use of a parachute,
the only acceptable conclusion in a top journal would be: The study
showed no advantage of wearing a parachute when jumping off a
plane. The very example can be used to lead the intention-to-treat
dogma ad absurdum. Imagine the same study with a properly timed
endpoint but a mix-up of groups published as an intention-to-treat
analysis only.
Misleading data in interventional
cardiology
Coronary stents
When coronary stents were introduced into clinical medicine,1,2
they were initially blamed for poor results for all the wrong reasons.
In contrast to the other so-called new devices of the 1980s, laser
therapy and atherectomy, stents were initially exclusively used for
bailout situations, i.e. poor results or abrupt closures after plain
old balloon angioplasty (POBA). Consequently, the results re-
mained fraught with high myocardial infarction and death rates des-
pite the clear-cut potential of stents to avoid just those. The other
so-called new devices were typically used electively in selected pa-
tients. They yielded results that were actually not competitive with
POBA but appeared superior to the stent results obtained in
patients already in a dire situation at the start of stenting.3,4 On
the other hand, it was already established as a fact that 70% of le-
sions yielded a result after POBA that was clinically perfect (no
abrupt or late closure and no significant restenosis) and could there-
fore not possibly be improved by a stent. In the pre-stent era, clin-
ically relevant vessel closures occurred in 5% and restenoses
creating symptoms or needing re-interventions in 25%. From
the 30% potential candidate lesions for a better result with the
use of a coronary stent, one would logically have to deduce 5%
of lesions with a negative outcome in spite or because of stenting.
This entails the impossibility to implant a stent in 2%, acute or
late stent thrombosis in 2%, and a worse type of restenosis
than expected without a stent in 1%. Simple math indicates that
only 25% of lesions attempted by percutaneous coronary interven-
tion (PCI) could possibly benefit from the implantation of a coron-
ary stent. Stenting in 100% makes sure that these 25% of lesions are
included. However, it unnecessarily imposes the risks of a stent to
the 75% of patients in whom a stent benefit to counterbalance the
stent risks is theoretically excluded. Trying to implant a stent only in
the 25% of lesions potentially benefitting from it entails even in the
most experienced hands that lesions would be misclassified and
some of those possibly benefitting from a stent would not get it.
So, while the coronary stents were still far from perfect, a coronary
stenting rate of 50% of lesions would probably have been ideal. A
publication showed a mortality rate in stented patients of 6 vs. 3% in
POBA patients at 6 years in one of the initial trials randomizing
stenting against POBA.5 This was driven by a myocardial infarction
rate of 8 vs. 4%, respectively. This study imposed conditional rather
than universal stenting but it was scotomized. Moreover,
meta-analysing the randomized trials comparing POBA with coron-
ary stents, it was quite conspicuously demonstrated in about 10 000
patients, when focusing on the potential of coronary stents to pre-
vent repeat PCI, that the maximum benefit of coronary stenting was
already attained with a stenting rate of 20–40%.6 That publication
was equally ignored, the era of default stenting having already
been ushered in. Moreover, the fairly small need for repeat PCI at
5% with a stenting rate of 20% or more with a bare-metal stent
(BMS) in that publication created a difficult background for showing
a significant reduction in re-interventions with the drug-eluting stent
(DES) about to be clinically introduced in 2003 when the paper was
published. Figure 1 nicely illustrates how the uncontested advantage
in terms of a reduced need for re-intervention of DESs over the ini-
tial BMSs was amplified in a scientifically questionable but purpose-
ful way, in that case beneficial for patients.7–11
While DESs got more praise than they deserved in the beginning,
they undeservedly fell on the dark side of popularity in the so-called
DES fire storm in 200612 (Figure 213). Focusing on the increased risk
for stent thrombosis during a narrow time window after the first
year, when the initial DESs were more prone to fissures in the
thin stent coat with endothelium than the BMSs, led to the fact
that the well-deserved upsurge of the DES was not only halted
but reversed. It took over 10 years to realize that this isolated depic-
tion of a problem, that would have been but a small concern if it had
been shown in full context, was a false reason to reserve DESs for
selected patients while all patients should have received them. Now-
adays, it is acknowledged that DESs have a reduced overall throm-
bosis risk in particular because of their low initial risk for stent
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thrombosis. While this initial benefit of DESs was caught up in part
by late stent thrombosis with the early generations of DESs, this is
no longer the case. Current DESs are safer throughout all follow-up
periods. And this was always independent of the antiplatelet regi-
men as it was also apparent in randomized trials with identical
follow-up drug schemes. While people prone to stent thrombosis
(e.g. not able to tolerate antiplatelets or required to discontinue
them for surgery) should have received a DES rather than a BMS
all along, they typically received a BMS for the good part of a decade
based on this misinterpretation of facts secondary to a number of
skewed reports on the matter 10 years ago. For instance, in pa-
tients with renal dialysis the use of DESs dropped from almost
90% to 50% in the USA. The adoption of 100% DES use in these
patients, justified on the basis of the now documented improved
outcome over that with BMSs including a significant survival bene-
fit14, was inappropriately delayed. Figure 315 depicts stent throm-
bosis rates with various stents. Figure 4 explains the propensity for
stent thrombosis or restenosis of the various stent designs.
Fractional flow reserve
While the assessment of the fractional flow reserve (FFR) to deter-
mine the haemodynamic significance of a coronary stenosis has
been around as a valid but largely ignored research tool for more
than a decade,16 it turned heads when papers were published that
appeared to prove a clinical benefit of using the FFR as a decision
tool whether or not to perform PCI.17 –20 Intuitively, it does not
make sense to cross a questionably significant coronary stenosis
with a guide wire just to perform a fairly complex provocation man-
oeuvre to determine the current haemodynamic significance in an
increased flow situation mimicking physical exercise. In particular,
in the realm of easy to implant and utterly safe DESs, fixing the lesion
is faster and about as safe as assessing it with the FFR. If the lesion
Figure 2 Distorted view of the stent thrombosis risk of early
drug-eluting stents. Pointing exclusively to the bottom panel
with the significantly increased risk for stent thrombosis during
months 12–15 of follow-up with drug-eluting stents or bare-metal
stents in an all-comers cohort of patients undergoing coronary
stenting, without putting it into relation of all events during the en-
tire follow-up period, put drug-eluting stents into ill-deserved dis-
repute. Not only the drastically reduced need for target lesion
revascularization but also decreased (albeit not to a significant ex-
tent) rates of overall death and overall stent thrombosis more than
compensated for the blemish after the first year, reported blown
out of proportion.
Figure 3 Stent thrombosis rates during follow-up after percu-
taneous coronary intervention of first-generation drug-eluting
stents with paclitaxel or sirolimus and a current drug-eluting stent
with everolimus. A typical bare-metal stent thrombosis risk is
added for reference.
Figure 1 Restenosis rates of the Bx-Velocity stent, a bare-metal
stent, and its sibling the Cypher stent, a drug-eluting stent. The left
panel shows the restenosis rates of the bare-metal stent examined
when bare-metal stent was the good guy (new thing) compared
with plain old balloon angioplasty in the VENUS7 and the VELVET8
trials. They were much lower than those in the RAVEL,9 the SIR-
IUS,10 and the E-SIRIUS11 randomized trials with exactly the same
bare-metal stent and comparable patients. This time the bare-
metal stent was the bad guy (old thing) used to highlight the virtues
of the modification of this bare-metal stent to an active
drug-eluting stent. Had the restenosis rates of the drug-eluting
stent been presented on the background of the restenosis rates
of the bare-metal stent as depicted while it benefited from the
fact that bare-metal stent was the new thing compared with plain
old balloon angioplasty (left side, plain old balloon angioplasty
results not displayed), its advantage would have been difficult to
discern. The common mechanism to make the old comparator
look worse and the new thing better than in reality is what was
conveyed and consequently retained from these seminal trials
introducing the drug-eluting stent.
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was indeed not yet haemodynamically significant, it most likely
would evolve to that point over time and assessing the FFR may
just be the reason why, as the FFR wire irritates the endothelium,
which can lead to a bout of plaque promotion. Even in the unlikely
event that this particular borderline lesion will nevermature to a sig-
nificant one in the patient’s life time, having put in amodern DES car-
ries an overall risk of only 1% to cause an adverse event, anytime.
The recently published 5-year follow-up of the FFR vs. angiography
for guidance of PCI in patients with multivessel coronary artery dis-
ease (FAME) trial21 claims to justify the use of the FFR for decision-
making by the fact that, over 5 years of follow-up, the non-stented
lesions that had a normal FFR at the moment of assessment did not
cause a significant number of problems. Logic and clinical experi-
ence render these findings hard to believe. The fact that, in FAME,
the main lesions were stented and only one additional (secondary or
tertiary) lesion was randomized to FFR-guided intervention may
provide an explanation. Neglecting such an unimportant additional
lesion may indeed not carry a palpable disadvantage over 5 years.
Neglecting the culprit lesion that brought the patient to the cath-
eterization laboratory must be less favourable than fixing it with a
modern DES. In fact this is what the FAME II trial showed albeit with-
out admitting to it (Figure 5).19
Figure 6 illustrates why PCI might be the better choice over con-
servative treatment, irrespective of trials stating the opposite.21,22
There are indeed several reports attesting PCI a survival benefit in
patients with stable coronary artery disease.23–25 They underscore
the importance of a long follow-up as coronary artery disease is as
much a slow killer as it appears to be a sudden killer,23 the transient
loss of life-saving power of early (drug-eluting) stents,24 and the fact
that 20% of myocardium at risk suffices to render PCI a life saver.25
Radial approach for coronary intervention
In the late 1980s, it was proposed to perform coronary angiog-
raphy26 and PCI27 through a puncture of the radial artery. This af-
forded immediate ambulation and a puncture site that was more
easily controllable than a femoral one. An initial enthusiasm was
curbed by the technically more challenging radial access and the
more intricate path to the coronary arteries. Only a negligible mi-
nority of operators continued to use that access on a routine basis28
until papers appeared stating that the radial access was prognostic-
ally superior to the femoral access in patients with acute coronary
artery disease.29,30 These publications are about to enforce a change
of paradigm31 which may not necessarily be in the interest of pa-
tients. Intuitively acute coronary syndromes, particularly large on-
going myocardial infarctions, require that the fastest path to
recanalization of the vessel be selected. On average, a femoral ap-
proach saves only a few minutes but this may already be significant
during acute myocardial infarction. Moreover, immediate mobiliza-
tion is not an issue in that setting. While it is possible that the
expected advantage of a femoral approach under these circum-
stances is forfeited by clinically relevant or even fatal access site
bleeding, this is avoidable by puncturing distal to the inguinal skin
crease, thereby precluding the possibility of retroperitoneal haem-
orrhage, and, perhaps, by using small catheters and closure devices.
An operator inexperienced with the radial approach feeling com-
pelled to use it in the middle of night in a patient with acute myocar-
dial infarction because of the survival benefit (in literature that may
at best be valid for radial aficionados) is a detrimental scenario for
the patient.
Closure of the patent foramen ovale
The potential of a net benefit by closing the patent foramen ovale
(PFO) is likely to be underestimated because of imperfect designs
of the respective randomized trials.32,33 As explained with the para-
chute example above, the assessment of the results was conducted
before the point in time when it can be assumed that the majority of
potentially preventable events will have happened. In contrast to
the parachute example, this is not minutes but rather decades
with regard to the PFO closure. A comparative study with random
allocation of patients to PFO closure or medical treatment with at
least one decade of follow-up did indeed show a mortality benefit
(yearly mortality rate of 0.4% with PFO closure and 1.1% without,
P ¼ 0.03).34 Likewise, the randomized evaluation of recurrent
stroke comparing PFO closure to establish current standard of
care treatment trial (RESPECT)33 showed a significant reduction
of stroke even according to the intention-to-treat principle when
comparing PFO closure with treatment with antiplatelet agents
only. This still leaves the option of life-long treatment with oral an-
ticoagulation as a valid alternative to PFO closure at least when
looking only at data of a follow-up of a couple of years. However,
an outpatient procedure lasting ,30 min, requiring no physical re-
strictions whatsoever thereafter, and producing practically no
Figure 4 Endothelial coverage of drug-eluting stents with sirolimus, paclitaxel, zotarolimus, or everolimus compared with that of a bare-metal
stent. The first-generation drug-eluting stent with sirolimus possessed too thin an endothelial coat, resulting in a low restenosis rate but a signifi-
cant risk for late thrombosis. The other first-generation drug-eluting stent with paclitaxel had an endothelial coat that was quite thin, particularly
on the stent struts themselves, and thereby vulnerable to erosion and stent thrombosis. Yet it also had thicker segments in between the struts,
creating a significant degree of restenosis. The newer drug-eluting stents with zotarolimus or everolimus yield a homogeneous endothelial coat,
thick enough to prevent erosion and stent thrombosis but still thin enough to result in significantly less restenosis than the bare-metal stent (far
right), featuring more lumen loss but a fairly low risk of late erosion and stent thrombosis.
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complications appears a much better deal than life-long oral antic-
oagulation with an ever accruing bleeding rate, not to mention the
cost and nuisance of drug intake. While the number needed to treat
to prevent one stroke with PFO closure appears high with 200 at
1 year, it is only 2 at 50 years,32,33 a life expectation not uncommon
when the question of PFO closure arises.
Transarterial aortic valve implantation
The advent of transarterial aortic valve implantation (TAVI) also
currently falls short of full clinical exploitation as a consequence
of adherence to evidence-based medicine in a way that is unfavour-
able to the patients. It is accepted that TAVI provides a mortality
benefit over medical treatment in inoperable35 or over surgical
treatment in high-risk patients.36 This was confirmed also in
the CoreValve US clinical trial randomizing variable risk patients
to either TAVI or surgical valve replacement37 and showing
that mortality in high-risk patients was significantly lower with
TAVI at 22% compared with 29% with surgical valve replacement
(P ¼ 0.04). Moreover, the aortic valve area remained larger with
TAVI up to 2 years and the transaortic pressure gradient lower.
The longevity of at least the two market leading TAVI valve types
can be assumed competitive with that of surgically implanted valves
after observing thousands of them for at least 5 years and seeing no
trend of premature valve degradation with TAVI compared with
surgery. Having digested all this, it appears counterproductive to
present patients to a heart team to decide whether they undergo
TAVI or surgical valve replacement. Obviously, the surgeons in
the heart team will point to the lack of randomized data in low-risk
surgical patients and claim them for open heart surgery. This is not in
the interest of the patients. It is safely deducible that a procedure like
TAVI that proved equally successful to and less risky and painful
than open heart surgery in difficult patients will also be feasible in
facile patients. It can also be anticipated that the banes of TAVI
such as paravalvular leaks or ruptures, ostial coronary obstruction,
need for pacemaker implantation, and access problems in the
peripheral vessels will be less common in the younger and healthier
Figure 5 Clinical outcome of the three groups examined in the
fractional flow reserve vs. angiography for guidance of percutan-
eous coronary intervention in patients with multivessel coronary
artery disease (FAME) II trial.19 The trial randomized 1220 patients
to percutaneous coronary intervention with a drug-eluting stent
or to conservative treatment (Medical) if their fractional flow re-
serve was ≤0.8 or followed them in a registry if the fractional flow
reserve was .0.8. The authors concluded that an abnormal
(FFR ≤ 0.8) had identified patients needing percutaneous coron-
ary intervention as the recurrence of symptoms prompting an
intervention was significantly higher in the conservative group
(middle panel) than in the percutaneous coronary intervention
group (left panel). This appears trivial considering that the patients
presented for a treatment of their symptoms. Those who did not
get to treatment must be more likely to rebounce asking for the
treatment than those who did get to treatment upfront. What ap-
pears rather strange is that the authors pointed to the efficacy of
the treatment also by using the fact that the registry patients (those
with a normal FFR . 0.8) had an almost identical event rate (right
panel) to that of the patients with a pathological FFR ≤ 0.8 and
percutaneous coronary intervention. It has to come to mind
here that if the registry patients also had undergone percutaneous
coronary intervention, their event rate most probably would have
been similarly reduced as the event rate was reduced in the treated
patients with a pathological FFR ≤ 0.8. So hypothetically a chance
was missed to free at least half of the patients with a normal
FFR . 0.8 from further events (right arrow), which mostly was a
need for percutaneous coronary intervention during follow-up.
Figure 6 Methaphorical depiction of coronary artery disease.
Life can be pictured as a steady forward motion on a high plane
that is narrow at the very beginning (newborn phase), rather broad
throughout young and middle age, but then gets narrower again
with increasing age. Deviating from the safe centre line occurs
with any kind of disease, in particular with coronary artery disease.
Although a coronary stenosis may be stabilized and the patient
does not necessarily feel the deviation from the safe centre line,
it appears reasonable to perform a percutaneous coronary inter-
vention to continue life again on the centre line, at least until a new
lesion pops up. The fractional flow reserve vs. angiography for
guidance of percutaneous coronary intervention in patients with
multivessel coronary artery disease (FAME)19,21 and also the clin-
ical outcomes utilizing revascularization and aggressive drug evalu-
ation (COURAGE)22 trials insinuate that it is justified not to
perform percutaneous coronary intervention by just assessing
whether the patients are alive and stable during a limited follow-up.
The diagram clearly suggests that the long-term course appears
more favourable in the example on the left side of the panel, i.e.
with percutaneous coronary intervention, even if there is no fur-
ther progression of disease which would render the already un-
favourable proximity to the dangerous precipice even more
precarious.
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patients. In a way, it is like having tested a pair of hiking boots by
conquering Mount Everest several times. It appears as ridiculous
to demand that before using these boots for climbing a hill, they
should again be thoroughly tested under these new circumstances.
While it is always commendable to consult with colleagues on a
particular patient, straightforward coronary situations and TAVI in
otherwise healthy persons do not need and are unlikely to benefit
from such a preoperative team discussion.
Conclusion
It is laudable that physicians, healthcare providers, drug producers,
and device manufacturers follow the request of authorities and eth-
ical committees to painstakingly test every new diagnostic or thera-
peutic approach in a randomized fashion and only introduce them
into the routine clinical management if they prove significantly bet-
ter than what was available previously. However, there are more
than a few situations where advantages are proved but not really
there or, vice versa, where waiting for the results of randomized
trials may preclude patients from an apparently good thing while
the trials are ongoing. In particular, preventive procedures such as
the closure of the PFO need studies with .10 years of follow-up
to be able to prove the expected benefit. Should all patients outside
such a trial be deprived of a potentially life-saving simple interven-
tion? Certainly not. Let us assume somebody develops a vaccination
against Alzheimer’s disease that is extremely likely to be effective
and have little side effects. According to modern evidence-based
medicine and publication rigour nobody should be vaccinated until
a correctly conducted randomized trial has been led to the pro-
jected final endpoint (40-year follow-up in that case) and published
in a reputable journal. Imagine the missed chances when reading that
paper in 2056 and thinking ‘I expected these excellent results of the
vaccination all along’.
Even if we are determined to perfectly juggle evidence-based
medicine, experience, and common sense with the patient’s best in-
terests in mind, our hands may be tied by a remuneration process
immune to common sense and lagging behind for what appears to
be eternities.38
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